Newark, NJ, May 30, 2022 (GLOBE NEWSWIRE) — As per the report published by Fior Markets, The global carrier screening market is expected to grow from USD 1.79 billion in 2019 to USD 6.50 billion by 2027, at a CAGR of 17.5% during the forecast period 2020-2027. The North American region stands as a promising market for carrier screening devices and is expected to grow at the highest CAGR during the forecast period. It is also expected to hold the largest market share during the forecast period. Prevalence of well-established healthcare infrastructure in the US and Canada, early detection of genetic & chromosomal disorders, growing awareness, and advanced screening techniques are the reasons to be credit for growth in the region.
Get Free Sample Copy: https://www.fiormarkets.com/report-detail/418335/request-sample
Key players in the global carrier screening market are Myriad Genetics, BGI Genomics, LabCorp, Fulgent Genetics, OPKO Health, Pathway Genomics, True Health, Luminex Corporation, Eurofins Scientific, Centogene, Progenity, Gene by Gene, Otogenetics Corporation, Thermo Fisher Scientific, Invitae, Sema4, Quest Diagnostics, MedGenome, Illumina, and Natera Inc. among others. Key companies are mainly focusing on developing new products, forming partnerships, and joint ventures to gain significant market share in the carrier screening market.
In 2017, Invitae acquired Good Start Genetics, a private molecular diagnostics firm centered on preimplantation…
